Medical Research Future Fund supports new biotech company tackling hard-to-treat cancers

Thanks to funding from the Medical Research Future Fund (MRFF), Ternarx will use world-leading technology to target difficult to treat cancers.

Date published:
General public

150,000 Australians are diagnosed with cancer every year. Most of them will be treated with drugs developed over 25 years ago, many of which may have severe side effects.

Ternarx will develop new protein degrader technology to create next-generation cancer medicines with greater efficacy and fewer side effects.

Ternarx is a WEHI spinout company funded through a $15 million grant from the MRFF's Frontier Health and Medical Research initiative.

Read the media release for more information about this new biotech company.

Researchers, apply for the 2022 Frontier Health and Medical Research grant opportunity which will provide $400 million over 9 years for:

  • ambitious, exploratory and ground-breaking programs of research
  • that deliver treatments for serious and incurable health conditions through a series of linked projects.

Help us improve

If you would like a response please use the enquiries form instead.